Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Protocol for the Development of Iranian Clinical Practice Guideline on Dyslipidemia Publisher



Ashoorion V1 ; Sarrafzadegan N2, 3 ; Shahidi S2 ; Bagherikholenjani F2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Humber River Hospital, Toronto, ON, Canada
  2. 2. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Faculty of Medicine, School of Population and Public Health, The University of British Columbia, Vancouver, Canada

Source: ARYA Atherosclerosis Published:2023


Abstract

INTRODUCTION: The prevention and control of dyslipidemia, as an important risk factor for cardiovascular diseases (CVDs), is a priority for the healthcare system to reduce the burden of these diseases. The purpose of this protocol is to outline the key steps of the first Iranian Dyslipidemia Clinical Practice Guideline development, which can be used by other researchers as a guide to design a standard, comprehensive, evidence-based, and local context-based guideline. METHOD: This guideline will be developed and reported according to the format of the World Health Organization (WHO) Handbook for Guideline Development. All members of the guideline development team will sign the declaration-of-competing-interests (DOI) forms. The development of the authors’ guideline will be supported by five groups: the steering committee (SC), the Guideline Developing Group (GDG), the systematic review (evidence synthesis) group, and the external review group. The authors will also establish a patient advisory group to inform guideline development by patients’ values and preferences. The SC and GDG will determine the scope of the guideline and will design PICO questions. The systematic review group will systematically search Embase, PubMed, Scopus, Web of Sciences, Cochrane Library, and Google Scholar from inception. The systematic review group will assess the risk of bias and create evidence summaries using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The recommendations of this guideline will be divided into strong recommendations and weak or conditional recommendations or suggestions. CONCLUSION: This clinical practice guideline will provide clinicians and healthcare professionals with new evidence-based recommendations for the diagnosis, management, and treatment of dyslipidemia in children and adults. © 2023, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Other Related Docs
16. Changes in Lipid Profile of Patients Referred to a Cardiac Rehabilitation Program, European Journal of Preventive Cardiology (2008)
23. Cvd Prevention in 2014: Advances in the Prevention of Cardiovascular Disease, Nature Reviews Gastroenterology and Hepatology (2015)
26. Trend of Atherosclerosis Risk Factors in Children of Isfahan, Asian Cardiovascular and Thoracic Annals (2001)
35. Dietary Patterns in Relation to Lipid Profiles Among Iranian Adults, Journal of Cardiovascular and Thoracic Research (2019)